ArticleClinical drug investigation2025

Response to Comment on: "Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E-Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations".

Shi-Jie Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.